Segment: Remediation Services

In this episode of Ask the Expert, published by PharmTech. Susan J. Schniepp and Siegfried Schmitt discuss how companies should approach preventing product recalls.

 

Link to the Video and Article on Pharmaceutical Technology

 

Ask the Expert Video Series

In this episode of Ask the Expert, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, discussed the recurring problem of product recalls and the proactive measures companies can take to prevent them. Schniepp and Schmitt identify microbial contamination, mislabeling, and physical contaminants like glass particulates as primary drivers of high-level recalls. Despite established quality systems, failures still occur due to systemic vulnerabilities such as reliance on subcontractors, production time constraints, and human error.

 

Discovery of these issues often occurs “in the field” when patients or doctors report adverse effects to the Adverse Drug Reporting Center. While the FDA usually does not mandate a recall, a company should respond to a high volume of complaints by initiating a voluntary recall to prevent patient harm. Microbial contamination is highlighted as a particularly challenging area because sterility assurance is a matter of probability rather than absolute testing. To combat this, companies should implement a comprehensive contamination control strategy that synthesizes data from environmental monitoring, gown swabs, and water systems.

 

Schniepp and Schmitt also address the serious risk of product mislabeling, which can lead to patients receiving the wrong dosage or drug. Such errors frequently occur before labeling even begins, such as vials are transported on carts with handwritten, temporary labels that are prone to human error. Because these vials look identical before labeling, a simple human mistake in marking a cart can lead to the wrong product being labeled correctly. To mitigate these risks, the quality unit should not remain isolated but should instead walk the shop floor to identify vulnerabilities that operations teams might overlook due to routine.

 

Prevention requires more than just possessing standard operating procedures. Companies must regularly test their recall procedures to ensure they can track and retrieve products across complex, global supply chains. Ultimately, the best defense against a recall is a “finely balanced” and well-understood quality system that incorporates International Council for Harmonisation Q10 risk management principles and maintains integrated controls across all manufacturing stages to provide total oversight.

Regulatory Compliance Associates (RCA), a Nelson Labs company, along with Sterigenics and Nelson Labs, part of Sotera Health, offer an integrated suite of services tailored for wearable and implantable connected medical devices. From concept to commercialization, they help navigate complex regulatory landscapes, ensuring quality, safety, and speed to market.

Why Choose Us?

  • Expert Guidance: Advisory services covering design, regulatory strategy, software development (including SaMD), cybersecurity, and risk management.
  • Advanced Testing: Material compatibility, biocompatibility, battery performance, microbial testing, and more.
  • Sterilization Excellence: Full-spectrum sterilization technologies including Gamma, EO, E-Beam, X-Ray, and Nitrogen Dioxide, with global GMP-certified facilities.
  • Global Reach: Serving over 5,000 customers across 62 facilities in 13 countries.

Integrated Ecosystem for Connected Care

RCA, Sterigenics, and Nelson Labs support the entire connected device lifecycle, ensuring seamless integration with electronic health records and AI-driven care platforms.

Learn how RCA, Sterigenics, and Nelson Labs can accelerate your connected medical device project with unmatched expertise and global capabilities.

Regulatory Compliance Associates® (RCA) Executive Pharma Compliance Expert & Principal Consultant, Anita Michael, recently shared important FDA updates impacting pharmaceutical manufacturers. With over 25 years of global regulatory and quality experience—including 16 years as the FDA’s Global Pharmaceutical Expert—Anita emphasizes the need for heightened inspection readiness.

 

Key FDA Updates

  • Unannounced Inspections Abroad: The FDA will now conduct unannounced inspections at foreign manufacturing facilities, similar to those already performed in the U.S. This expansion ensures drug substances, finished products, and critical excipients entering the U.S. meet safety and quality standards.
  • Rigorous Reviews: Expect science-based audits across manufacturing operations and quality systems. Companies should ensure their
  • six quality systems (Quality, Production, Laboratory, Facilities & Equipment, Materials, and Packaging/Labeling) are fully inspection-ready.
  • Pre-Approval Program Updates: The FDA has refined its pre-approval inspection focus to include:
    • Readiness for commercial manufacturing (QMS and six systems)
    • Conformance to application and data integrity requirements
    • Commitment to quality and pharmaceutical development
    • Audit preparedness and documentation management

Preparing for Compliance

  • To stay ahead, companies should:Conduct robust internal and external audits
  • Maintain a centralized FDA document repository
  • Ensure subject matter experts are prepared to address complex regulatory questions

 

Why It Matters

These changes highlight the FDA’s commitment to protecting U.S. patients by ensuring consistent global manufacturing standards. Proactive preparation will be critical for pharmaceutical companies with international facilities or partnerships.

 

Need support preparing for FDA inspections or audits? Contact RCA today to speak with our compliance experts and ensure your organization is inspection-ready.

503B outsourcing facilities play a critical role in addressing drug shortages and providing large-scale compounded medications. However, with this privilege comes the responsibility of adhering to stringent FDA regulations under Current Good Manufacturing Practices (CGMP). Repeated violations can lead to FDA warning letters, product recalls, and even shutdowns. Understanding common pitfalls is essential for maintaining compliance and ensuring patient safety.

 

In this blog, we examine some of the most frequent deficiencies cited in FDA warning letters to 503B facilities and how you can proactively prevent them.

 

Inadequate Aseptic Processing Controls

A recurring theme in FDA inspections is the failure to maintain proper aseptic technique and conditions. This includes:

  • Inadequate aseptic employee techniques
  • Improper personnel gowning and behavior
  • Poor cleanroom design and maintenance
  • Inadequate airflow and HEPA filter placement
  • Insufficient monitoring of environmental conditions
  • Poor cleaning, disinfection and sanitation controls

How to Avoid: Conduct a comprehensive GMP review of your aseptic processes, validate cleanroom performance, and implement rigorous training for all personnel involved in sterile compounding.

 

Deficient Environmental Monitoring Programs

Many facilities fall short in establishing adequate environmental monitoring (EM) protocols. Common issues include:

  • Irregular or infrequent sampling
  • Lack of meaningful trending and analysis
  • Delayed response to out-of-specification (OOS), alert and action results
  • Insufficient timely corrective actions

How to Avoid: Develop a robust EM and PM program that includes real-time data collection, regular review of trends, and timely corrective actions. Use EM data as a proactive quality tool, not just a compliance checkbox.

 

Incomplete or Inaccurate Documentation

Documentation is the backbone of GMP compliance. FDA has consistently cited 503B facilities for:

  • Missing batch records, incomplete entries and poor GDPs
  • Failure of thorough and timely deviations and investigations
  • Lack of CAPAs
  • Lack of traceability in production processes

How to Avoid: Enforce strict documentation procedures and requirements. Ensure all entries are legible, contemporaneous, original, accurate and reviewed regularly by quality assurance experts. Implement validated electronic systems where feasible to reduce human error.

 

Insufficient Process Validation

Many 503B facilities do not adequately validate their compounding processes. This includes:

  • Limited or no validation of sterile filtration and filling processes
  • Absence of complete media fill simulations
  • Failure to scientifically demonstrate repeatability and reliability of processes

How to Avoid: Develop and execute a thorough validation master plan (VMP) and perform validation studies. Conduct media fills under worst-case conditions and ensure all critical parameters are tested and documented and the facility is operating in a state of control.

 

Poor Quality Unit Oversight

The FDA expects a robust and independent quality unit (QU) to oversee all aspects of production. Common failures include:

  • QU lacking authority or involvement in decision-making
  • Quality responsibilities split among unqualified personnel
  • Inadequate review of batch records and investigations
  • Poor or incomplete quality SOPs

How to Avoid: Empower your quality unit with the necessary resources, training, and authority to act independently. Quality should not be siloed—it must be embedded into every layer of your operation.

 

Final Thoughts

503B outsourcing facilities operate under intense regulatory scrutiny, and for good reason: they are entrusted with producing high risk sterile medications on a large scale. By studying past deficiencies and strengthening internal systems, facilities can avoid the missteps that lead to enforcement actions.

 

Stay proactive, stay informed, and remember that compliance is not a one-time task—it’s an ongoing commitment to excellence.

 

Need help assessing your compliance and strengthening your quality systems? Contact RCA today to get expert guidance tailored to your facility’s needs.